AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01973946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Alert and Coaching
Description: Patients heard self-care messages when they reported a symptom was present. The Symptom Alert and Coaching intervention alerted study nurse practitioners of unresolved symptoms daily. The NPs responded to all alerts generated by patients and using evidence based guidelines, called patients to further assess and to intensify symptom treatment.
Study NCT01975818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY 85-3934)
Description: Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets
Study NCT01975818 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa/beta
Study NCT00238667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet (Aspirin, Dipyridamole, clopidogrel)
Study NCT00238667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)
Study NCT04566627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yo Sé Lo Que Quiero programl
Description: Yo Sé Lo Que Quiero program is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis.
Study NCT02209337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRS
Study NCT04561804 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)
Description: The participants will receive nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet will be composed of carbohydrates (CHO;35%), fats (40-50%), and proteins (20-25%), and will be tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings will be determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants will not be instructed to restrict calories, but to reduce carbohydrate based on their glycemic load.~The subjects will be instructed about appropriate food choices, and each subject was provided a diet information booklet containing food list, sample menus and recipes
Study NCT01351623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.
Study NCT02054325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol with Glucose
Description: An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
Study NCT02054325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
Study NCT01649570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
Study NCT01326728 — intervention group
Intervention type: BIOLOGICAL
Intervention: Allogeneic stem cell transplant
Description: Donors will undergo cell collection and recipients will receive cells (allotransplant).
Study NCT01159912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate inhalation powder, 250 µg
Study NCT01159912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Fluticasone furoate inhalation powder, 100 µg
Study NCT01159912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo inhalation powder
Study NCT01159912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder
Study NCT01159912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder
Study NCT03805009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RAGT)
Description: The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
Study NCT04288895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 5 - 20 mg/day flexible-dose vortioxetine, tablets, orally
Study NCT05568602 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dexamethasone suppression test
Description: 1 mg Dexamethasone overnight suppression test for screening of hypercortisolism
Study NCT02301936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg fixed dose combination (FDC) tablet administered orally once daily
Study NCT02540538 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBVaxPro
Description: 3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.
Study NCT02540538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBAI20
Description: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.
Study NCT04563000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days
Study NCT04563000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
Study NCT02506478 — intervention group
Intervention type: OTHER
Intervention: Beverage procurement
Description: All Emergency Department patients will be approached to ask their beverage preferences in a randomly permuted data collection form. If they would like juice, the flavor will be recorded and the juice (and/or water) will be procured by a research assistant if the patient would like that, though the actual procurement of the juice is not part of the study.
Study NCT02926469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Using Virtual Reality during labor
Study NCT00408603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voreloxin Injection
Description: All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.
Study NCT04139057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBV-specific TCR-T cell with anti-PD1 auto-secreted element
Description: Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
Study NCT04087954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma reduction program
Description: Participants in the intervention group received treatment as usual, supported with stigma reduction program booklets each fortnight for 26 weeks. The stigma reduction program includes three modules; psychoeducation, cognitive behavioural therapy and social skills training. The program aims to enhance patient understanding of Schizophrenia and foster communication skills which supposed to increase self-confidence and strengthen communication networking with society.~Psychoeducation module purposes at introducing about the concepts of schizophrenia, providing patient with essential information about schizophrenia, including nature of disease, sign/symptoms, treatment strategies, side effects of medication. Social Skills Training (SST) module purposes at fostering communication skills among patient diagnosed with schizophrenia. This assists the participants to be re-integrated in the society and build a harmonious atmosphere in the community.
Study NCT05261971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac 400 MG
Description: Patients were asked to drink a tablet containing 400 mg of etodolac every 24 hours with a glass of water.
Study NCT05261971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiocolchicoside
Description: Patients were asked to drink a tablet containing 4 mg of thiocolchicoside every 24 hours with a glass of water.
Study NCT01923116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPV-16 vaccine
Description: Vaccination with SLP-HPV-01® with or without interferon-a injections.
Study NCT04181944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Treatment Group
Description: be specific
Study NCT01102803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy (CBT)
Description: The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
Study NCT01102803 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Individual Cognitive Behavioral Therapy (CBT)
Description: The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
Study NCT01102803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: D-Cycloserine
Study NCT01102803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill
Study NCT04254744 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane inhalation for anesthesia
Study NCT03920150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Patient will be treated with 3 doses of alcoholic solution for 3 months.
Study NCT03920150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D oily capsules
Description: Patient will be treated with 3 capsules for 3 months.
Study NCT03920150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D oily capsules
Description: Patient will be treated with weekly capsules for an individually calculated number of weeks.
Study NCT02336763 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study NCT02336763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04403750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined laser-surgical technology of RRD treatment
Description: 1. Nd-YAG laser excision of the vitreoretinal traction zone~2. Pneumatic retinopexy (10% C3F8)~3. barrier laser photocoagulation around retinal break after retinal attachment (2-3 days after pneumatic retinopexy)
Study NCT01667107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Study NCT01667107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calogen®
Study NCT03061461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rESWT
Description: All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin, Smith \& Nephew, Inc. Advanced Wound Management; Fort Worth, TX, USA).~In addition, patients in arm rESWT will receive rESWT between Steps 2 and 3 of standard care as outlined in arm description rESWT.
Study NCT03061461 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rESWT
Description: All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with sham rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin).~In addition, patients in arm Sham rESWT will receive sham rESWT between Steps 2 and 3 of standard care as outlined in arm description Sham rESWT.
Study NCT03536390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
Description: Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
Study NCT03536390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06012383 — intervention group
Intervention type: DRUG
Intervention: Bortezomib
Description: Alvocade® was given with a dose of 1.3 mg/m2.
Study NCT00947778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 sessions of evaluation tests
Description: 3 sessions of evaluation tests, each session during 15 days
Study NCT00947778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 training session
Description: 20 sessions of 30 minutes by week during 24 semaines
Study NCT04536610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Providing structured osteoporosis education
Description: The OP education was performed in groups of 4-5 people by a single physician with a single session in the form of verbal expression via slide, with a duration of 20 minutes.
Study NCT04536610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Giving informative leaflet
Description: Leaflets containe the same information as the OP education program
Study NCT04536610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Giving informative leaflet
Description: Leaflets containe the same information as the OP education program
Study NCT04978142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Non-invasive neuromodulation employing a direct current, applied using a DC STIMULATOR PLUS manufactured by NeuroConn Technology by NeuroCare. This is a micro-processor-controlled constant current source. It meets the highest safety standards thanks to (hardware- and software-based) multistage monitoring of the current path. By continuously monitoring electrode impedance it can detect insufficient contact with the skin and automatically terminate stimulation. This is a reliable method of avoiding any injury to the patient.
Study NCT04978142 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Non-invasive neuromodulation employing a direct current, applied using a DC STIMULATOR PLUS manufactured by NeuroConn Technology by NeuroCare. This is a micro-processor-controlled constant current source. It meets the highest safety standards thanks to (hardware- and software-based) multistage monitoring of the current path. By continuously monitoring electrode impedance it can detect insufficient contact with the skin and automatically terminate stimulation. This is a reliable method of avoiding any injury to the patient.
Study NCT01674335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Operant Learning
Description: The present therapist manual focuses on the operant learning approach, which emphasizes the use of positively reinforced activity quotas that are time and/or goal contingent, rather than pain-contingent, using a gradually increased activity-rest cycling approach (Fordyce, 1976).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months.
Study NCT01674335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Energy Conservation
Description: The present therapist manual focuses on the energy conservation approach, which emphasizes management of participant energy expenditure, and seeks to achieve a balance between accomplishing important day-to-day activities and resting in order to reduce or avoid pain and fatigue (Hammond, 2004).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months.
Study NCT02550522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton
Study NCT03902847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor imagery
Description: All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.
Study NCT03902847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: A video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.
Study NCT03902847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor Control Exercises
Description: The subjects were asked to perform 3 sets, of 10-12 repetitions each six exercise, with a total duration of approximately 30-35 minutes. The exercises program had to do it once a day, 6 days a week, for 3 weeks.
Study NCT00958620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Wave Therapy
Description: Extracorporal shock-wave therapy
Study NCT00958620 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Shock Wave Therapy
Description: Extracorporal shock-wave therapy
Study NCT03049735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix (40 mg) tablet administered orally once daily.
Study NCT03049735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
Study NCT03049735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
Study NCT03049735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
Study NCT03049735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Relugolix placebo
Description: Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
Study NCT04543604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leatlet + visual aid (pictogram)
Description: The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
Study NCT04543604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet + no visual aid (no pictogram)
Description: The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
Study NCT01439919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR411298
Description: Form: tablet~Route: oral administration with food
Study NCT01439919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for SSR411298)
Description: Form: tablet~Route: oral administration with food
Study NCT02628301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hypercaloric diet
Description: Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.
Study NCT02628301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normocaloric diet
Description: Normocaloric diet